A Randomized, Open-label, 2×2 Crossover, Phase I Study to Evaluate the Bioequivalence of Single Oral Dose of TAK-536 Pediatric Formulations and TAK-536 Commercial Tablet in Healthy Adult Male Subjects

Trial Profile

A Randomized, Open-label, 2×2 Crossover, Phase I Study to Evaluate the Bioequivalence of Single Oral Dose of TAK-536 Pediatric Formulations and TAK-536 Commercial Tablet in Healthy Adult Male Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Jul 2016

At a glance

  • Drugs Azilsartan (Primary)
  • Indications Hypertension
  • Focus Pharmacokinetics
  • Sponsors Takeda
  • Most Recent Events

    • 01 Sep 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov
    • 27 Apr 2015 Status changed from not yet recruiting to recruiting as per ClinicalTrials.gov record.
    • 31 Mar 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top